Cargando…

Genetic Variation in Kruppel like Factor 15 Is Associated with Left Ventricular Hypertrophy in Patients with Type 2 Diabetes: Discovery and Replication Cohorts

Left ventricular (LV) hypertrophy (LVH) is a heritable trait that is common in type 2 diabetes and is associated with the development of heart failure. The transcriptional factor Kruppel like factor 15 (KLF15) is expressed in the heart and acts as a repressor of cardiac hypertrophy in experimental m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Sheila K., Wai, Bryan, Lang, Chim C., Levin, Daniel, Palmer, Colin N.A., Parry, Helen M., Velkoska, Elena, Harrap, Stephen B., Srivastava, Piyush M., Burrell, Louise M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405178/ https://www.ncbi.nlm.nih.gov/pubmed/28400202 http://dx.doi.org/10.1016/j.ebiom.2017.03.036

Ejemplares similares

Left ventricular hypertrophy in experimental chronic kidney disease is associated with reduced expression of cardiac Kruppel-like factor 15
por: Patel, Sheila K., et al.
Publicado: (2018)

Kruppel-Like Factor 15 Is Critical for the Development of Left Ventricular Hypertrophy
por: Patel, Sheila K., et al.
Publicado: (2018)

The Receptor for Advanced Glycation End Products (RAGE) Is Associated with Persistent Atrial Fibrillation
por: Lancefield, Terase F., et al.
Publicado: (2016)

The CTGF gene −945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes
por: Patel, Sheila K, et al.
Publicado: (2012)

Does Krüppel Like Factor 15 Play an Important Role in the Left Ventricular Hypertrophy of Patients with Type 2 Diabetes?
por: Zhao, Yuguang, et al.
Publicado: (2017)

From gene to protein—experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension
por: Patel, Sheila K., et al.
Publicado: (2014)

Does left ventricular hypertrophy affect cognition and brain structural integrity in type 2 diabetes? Study design and rationale of the Diabetes and Dementia (D2) study
por: Patel, Sheila K., et al.
Publicado: (2017)

Genetic variants predicting left ventricular hypertrophy in a diabetic population: a Go-DARTS study including meta-analysis
por: Parry, Helen M, et al.
Publicado: (2013)

Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention
por: Mohan, Mohapradeep, et al.
Publicado: (2021)

Diminazene Aceturate Improves Cardiac Fibrosis and Diastolic Dysfunction in Rats with Kidney Disease
por: Velkoska, Elena, et al.
Publicado: (2016)

Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition
por: Burrell, Louise M., et al.
Publicado: (2017)

Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study
por: Brown, Alexander J.M., et al.
Publicado: (2017)

A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
por: Brown, Alexander J M, et al.
Publicado: (2020)

Short-Term Treatment with Diminazene Aceturate Ameliorates the Reduction in Kidney ACE2 Activity in Rats with Subtotal Nephrectomy
por: Velkoska, Elena, et al.
Publicado: (2015)

Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control
por: Wai, Bryan, et al.
Publicado: (2012)

Left ventricular hypertrophy: is it really?
por: Mikolich, J Ronald, et al.
Publicado: (2013)

Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease
por: Ramchand, Jay, et al.
Publicado: (2018)

Experimental and Human Evidence for Lipocalin‐2 (Neutrophil Gelatinase‐Associated Lipocalin [NGAL]) in the Development of Cardiac Hypertrophy and Heart Failure
por: Marques, Francine Z., et al.
Publicado: (2017)

Recent Discoveries on the Involvement of Krüppel-Like Factor 4 in the Most Common Cancer Types
por: Taracha-Wisniewska, Agnieszka, et al.
Publicado: (2020)

Angiotensin-(1–7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy
por: Velkoska, Elena, et al.
Publicado: (2010)

Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition
por: Velkoska, Elena, et al.
Publicado: (2009)

Moexipril and left ventricular hypertrophy
por: Chrysant, George S, et al.
Publicado: (2007)

Simplifying the diagnosis of left ventricular hypertrophy: is left ventricular mass to volume ratio constant in children throughout growth?
por: Lee, Simon, et al.
Publicado: (2016)

Left Ventricular Hypertrophy and Ventricular Tachyarrhythmia: The Role of Biomarkers
por: Bacharova, Ljuba, et al.
Publicado: (2023)

Kruppel-like factor 15 is required for the cardiac adaptive response to fasting
por: Sugi, Keiki, et al.
Publicado: (2018)

Krüppel-like factor 15 in liver diseases: Insights into metabolic reprogramming
por: Chen, Hao, et al.
Publicado: (2023)

Myocardial Energetics in Left Ventricular Hypertrophy
por: Jameel, Mohammad N, et al.
Publicado: (2009)

Isolated Right Ventricular Apical Hypertrophy
por: Yamashita, Kentaro, et al.
Publicado: (2020)

Is hypertensive left ventricular hypertrophy a cause of sustained ventricular arrhythmias in humans?
por: Nadarajah, R., et al.
Publicado: (2021)

Cardiovascular Magnetic Resonance for the Differentiation of Left Ventricular Hypertrophy
por: Burrage, Matthew K., et al.
Publicado: (2020)

Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy
por: Sadasivan, Chandu, et al.
Publicado: (2020)

The Association of Growth Differentiation Factor-15 with Left Ventricular Hypertrophy in Hypertensive Patients
por: Xue, Hao, et al.
Publicado: (2012)

Left Ventricular Hypertrophy May Be Transient in the Emergency Department
por: Shoenberger, Jan M., et al.
Publicado: (2009)

Participation of Krüppel-like Factors in Atherogenesis
por: Kotlyarov, Stanislav, et al.
Publicado: (2023)

Interstitial expansion in pressure overload left ventricular hypertrophy
por: Treibel, Thomas A, et al.
Publicado: (2013)

Krüppel-like Factor 15: A Potential Therapeutic Target For Kidney Disease
por: Wang, Lefeng, et al.
Publicado: (2019)

Krüppel-Like Factors: Crippling and Uncrippling Metabolic Pathways
por: Pollak, Nina M., et al.
Publicado: (2018)

The effect of levothyroxine treatment on left ventricular function in subclinical hypothyroidism
por: Nakova, Valentina Velkoska, et al.
Publicado: (2018)

Discrepancy between left ventricular hypertrophy by echocardiography and electrocardiographic hypertrophy: clinical characteristics and outcomes
por: Seko, Yuta, et al.
Publicado: (2021)

Electrocardiographic Criteria for Left Ventricular Hypertrophy in Children
por: Rijnbeek, Peter R., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_1qea5qhsic88i00kc0fv94k73k